New Stock News | mRNA drug company Sinobioway Biotechnology plans to go public in Hong Kong or raise about $200 million.

According to reports, mRNA drug developer Shenxin Biotechnology plans to list in Hong Kong. The company is in potential IPO discussions with CICC and FuRui Research, with the earliest listing next year and possible fundraising of around $200 million. The report quoted sources as saying that details such as the IPO size and timing are still in the preliminary discussion stage and may change. Public information shows that Shenxin Biotechnology was established in 2019 and is one of the few companies globally that master the core technology of LNP bottom design. The company has deployed a mRNA-LNP technology platform with independent intellectual property rights worldwide, and has built a library of over 5,000 ionizable lipid resources for screening LNP carriers suitable for different therapeutic scenarios. The company has established multiple internal R&D pipelines in infectious disease vaccines, rare diseases, and tumor immunology fields. According to data from Qichacha, Shenxin Biotechnology has gone through several rounds of financing, with investors including Huaxing Capital, DHVC, CPE Source Peak, Qianhai Fyuan Capital, E Fund Management, Lanhai Capital, China Creation Ventures, Qianhai Mothers Fund, Orient Securities Capital, Junlian Capital, Chongqing Zhifei Biological Products, and Lanting Capital.